# Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

> **NCT06432036** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Stage I Renal Cell Cancer
- Stage II Renal Cell Cancer

## Interventions

- **PROCEDURE:** Angiogram
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **RADIATION:** Radioembolization
- **PROCEDURE:** Single Photon Emission Computed Tomography
- **OTHER:** Survey Administration
- **RADIATION:** Yttrium Y 90 Glass Microspheres

## Key facts

- **NCT ID:** NCT06432036
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06432036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06432036, "Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06432036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*